Erlotinib in lung cancer - molecular and clinical predictors of outcome.

By Ming-Sound Tsao, A. Sakurada, J. Cutz, Chang-Qi Zhu, S. Kamel‐Reid, J. Squire, I. Lorimer, Tong Zhang, Ni Liu, M. Daneshmand and 9 more. New England Journal of Medicine, 2005

1,704 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c22db5130dc84dde5df6bc71c1ac784e3b8101a0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Jordi Bruix1 , 2
2. V. Mazzaferro
3. J. Llovet
4. William Pao
5. G. Gores
6. J. Settleman
7. R. Weinberg

In Pulmonary and Respiratory Medicine

1. G. Gores
2. Marc Ladanyi
3. William Pao

Citations in the corpus

• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Similarly, EGFR mutational status in non-small cell lung cancer identifies a subgroup of responders to tyrosine kinase inhibitors [172].”
• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors (2013, positive): “Finally, comparisons of EGFR amplification and EGFR mutation as predictors of response and clinical outcome in earlier clinical trials of TKI versus placebo in the second-line (or greater) setting were hampered by the small size of the subsets of patients with available molecular data, in particular”
• Oncogenic PI3K deregulates transcription and translation (2005, background): “Therapy with these inhibitors increased survival times of patients with tumours that express EGF”
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009, methodology): “based on clinical features commonly associated with EGFR mutation.(20,21) As a result, the cohort of screened patients was enriched for women, for never/light smokers, and for patients with adenocarcinomas or adenocarcinomas with bronchioloalveolar features (ie, BAC; Table 1).”
• Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. (2014, background): “This is the case of amplification of Her2/neu and responders to trastuzumab in breast cancer [96], EGFR mutational status or ALK status and response to erlotinib and crizotinib, respectively, in non-small cell lung cancer [97,98], and B-RAF mutations to identify responders to B-RAF inhibitors in mel”